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Summary.-S.c. injection of tumour cells or small pieces of tumour irradiated to
a dose of 22,000 rad evoked resistance to live challenge with the same tumour (a
CBA strain fibrosarcoma induced with methylcholanthrene) 14 days later. This
resistance was, however, over-ridden if the challenging inoculum was sufficiently
large, and did not develop if the cells were irradiated to 100,000 rad.
The resistance evoked by injection of 106 irradiated tumour cells was impaired
by i.p. injection of 1 4 mg C. parvum 5 days before, and virtually abolished by a
similar injection 11 days after, the irradiated cells. The effect of s.c. injection of a
mixture of 106 irradiated cells and C. parvum 14 days before live challenge depended
on the dose of C. parvum. With 0*7 mg the development of resistance was largely
but not completely abrogated; 0-35 mg resulted in a lesser degree of abrogation,
and 0-09 mg or 0*02 mg had little or no effect.
IT was reported by Woodruff and
Dunbar (1973) that simultaneous s.c.
injection of irradiated tumour cells and
i.p. injection of C. parvum to mice with
small but actively growing fibrosarcoma
isotransplants caused a more prolonged
remission than either treatment alone.
On the other hand Smith and Scott
(1972) found that administration of C.
parvum 7 days before immunization with
irradiated tumour cells diminished the
protective effect of the immunization,
as judged by the effect of subsequent
challenge with viable tumour cells.
Taken together, these findings have
important implications both for our under-
standing of the mode of action of C.
parvum as an immunopotentiating agent
and in relation to the possible use of C.
parvum in combination with active speci-
fic immunization for the treatment of
patients with cancer. The present experi-
ments were therefore undertaken to see
whether the observations of Smith and
Scott could be repeated with our tumour
system. As apreliminary we have studied
the effect of variations in the preparation
of the irradiated tumour material, the
route of injection, and the quantity
injected, on immunization in the absence
of C. parvum.
MATERIALS AND METHODS
Mice.-7-9 week-old female CBA mice
were used throughout.
Tumour.-The tumour was a fibrosarcoma
induced in a CBA female mouse with methyl-
cholanthrene, and was in its 15th-17th
transplant generation. In most of the
experiments, we have used tumour cell
suspensions prepared with pronase as de-
scribed previously (Woodruff, Inchley and
Dunbar, 1972), but for immunization we
have also used small pieces of recently
excised tumour. Tumour cells and pieces
of tumour used for immunization were
irradiated with aWestinghouse x-ray machine
operating at 220 kV and 15 ma with HVL
of 1-2 mm Cu under conditions of maximum
back scatter, at a dose rate of 274 rad/min.
Assessment of results.-The results were
assessed by comparing the incidence of
tumours and relative growth rates in the
various treatment groups.
Differences in the incidence of tumours
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analysis unnecessary, but when this was
not the case the probability (P) of the
observed difference being due to random
sampling, from published values applicable
(unless otherwise stated) to a single-tailed
test for fourfold tables (Diem and Lentner,
1970), is shown in the section on results.
When more than half the mice in a group
developed tumours the group, mean relative
growth rate, together with its95% confidence
limits (i.e. t X standard error), was cal-
culated. Only those mice in the group
which actually developed tumours were
included, and the relative growth rate for
each individual treated mouse was taken
as the ratio of the tumour diameter in that
mouse on a particular day to the mean
tumour diameter on the same day in un-
treated mice challenged with the same
number of viable cells. The day was chosen
so that the mean tumour diameter in the
control mice was between 15 and 18 mm;
it ranged from Day 14 to Day 24 depending
on the size ofthe challenging inoculum.
Corynebacterium parvum.-A formalin-
killed suspension of C. parvum strain CN
6134 (Batch WE2174) was kindly provided
by Dr. A. Weinberg of the Wellcome Re-
search Laboratories. In some experiments
0'2 ml of this suspension (containing 1-4 mg
dry wt. organisms) was injected i.p.: in
others C. parvum suspension mixed with
irradiated tumour cells was injected s.c.
RESULTS
The results are summarized in Tables
I and II.
Pretreatment with irradiated cells alone
Mice injected s.c. with 106 irradiated
cells (22,000 rad) were almost completely
resistant to challenge with 104 or 105
viable tumour cells 14 days later, but
were susceptible to challenge with 106
or 107 cells (Table I and group 2, Table
II). There is a suggestion (Table I) that
larger (107 or 108) doses of irradiated
cells were marginally less effective than
106 cells (comparison ofthe poolednumber
of takes after immunization with 107
or 108 irradiated cells with the number
after immunization with 106 irradiated
cells in a two-tailed test gives P = 0.02).
J.v., and possibly also i.p., injection of
106 irradiated cells was less effective
than s.c. injection. Irradiated pieces of
tumour tissue were as effective as irradi-
ated cell suspensions. Cells irradiated
to 100,000 rad did not render mice
resistant to subsequent live challenge
(Table I).
Pretreatment with C. parvum alone
In conformity with many previous
experiments with this tumour, i.p. injec-
tion of 1-4 mg C. parvum 3 days before
s.c. inoculation of 105 viable tumour cells
resulted in slower development of the
tumour though it did not significantly
influence the number oftakes. A similar
injection 19 days before tumour inocula-
tion, and s.c. injection in various doses
TABLE I.-Effect of Pretreatment with Irradiated Tumour Cells or Pieces of Tumour
on the Incidence of Tumours Followin.g Challenge with 104 Viable Tumour Cells 14
Days Later
Pretreatment with irradiated tumours
t A~~~~~~~~~~~~
Form
Controls-no pretreatment
Pronase suspension from
excised tumour
Pieces of excised tumour
Dose of
irradiation
(rad) Route
22,000 s.c. injection
i.p. injection
i.v. injection
100,000 s.c. injection
22,000 s.c. implantation
Tumour incidence after
a ~ live challenge
No. of ,A_
irradiated No. of mice No. of mice
cells challenged with tumours
36 35
104 6 1
106 33 0
107 5 2
108 6 1
106 6 1
106 6 3
106 6 5
106 6 0
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TABLE ll.-Effect of Pretreatment with Irradiated (22,000 rad) Tumour Cells and
C. parvum on the Incidence and Growth ofTumour after Challenge with Viable Tumour
Cells
Group
No.
1
Pretreatment
Nil
2 106 irradiated cells s.c. Day - 14
3 C. parvuml 4 mg i.p. Day -19
4 C. parvum 1 4 mg i.p. Day- 3
5 C. parvum 0 7 mg s.c. Day -14
6 C. parvum 0 09 mg s.c. Day -14
7 106 irradiated cells s.c. Day -14
± 1 4 mg C. parvum i.p. Day -19
8 106 irradiated cells s.c. Day -14
±1 -4 mg C. parvum i.p. Day- 3
9 106 irradiated cells mixed with
0 7 mg C. parvum s.c. Day -14
10 106 irradiated cells mixed with
0 - 35 mg C. parvum s.c. Day -14
11 106 irradiated cells mixed with
0 09 mg C.parvum s.c. Day -14
12 106 irradiated cells mixed with
0*02 mg C. parvum s.c. Day -14
Live challenge
on Day 0.
No. of
viable cells
104
105
106
107
104
105
106
107
104
105
105
105
107
106
104
105
105
104
105
107
105
106
107
105
106
107
105
106
107
No. of
mice
challenged
36
24
12
12
33
24
12
12
12
12
6
6
6
6
13
6
6
6
12
6
6
6
6
6
12
6
6
6
6
No. of
mice with
tumours
35
24
11
12
0
2
11
12
11
12
5
6
6
6
3
2
5
2
12
6
3
5
5
0
8
5
2
5
4
Mean relative growth
rate in mice which
developed tumour*.
Mean ±95%
confidence limits
0 58±0 16
0-95±0 14
0 78±0 16
0 93±0 06
0-49±40-08
1 04±0 07
0 87±0-25
0 88±0 02
0 53±0 20
0-81±0-15
0-95-4 0-05
0-47±0-24
0-85±0-21
0-45±0- 10
0 72±0 -21
0-56±0-27
0-71±0-48
* For explanation see text.
before tumour inoculation, had no signi-
ficant effect.
Pretreatment with irradiated cells and C.
parvum
In mice which received 106 irradiated
cells s.c. on Day -14 and 1.4 mg C.
parvumn on Day -3, the incidence of
tumours greatly exceeded that in mice
which received irradiated cells alone
(comparing groups 8 and 2 of Table II
after challenge with 105 viable cells:
P -- 0 001), but did not differ significantly
from the incidence in untreated mice;
and the mean growth rate, though slower
than in untreated mice, was similar to
that in mice which received C. parvum
alone (Table II, group 4).
In mice which received 1-4 mg C.
parvum i.p. on Day -19 and 106 irradiated
cells s.c. on Day -14, the incidence of
tumours was greater than in mice which
received irradiated cells alone (comparing
groups 7 and 2 of Table II after challenge
with 104 and 105 viable cells, the difference
in each case is just significant at the
P = 0*05 level), and very much less
than in untreated mice (comparing groups
7 and 1 of Table II after challenge with
104viable cells: P < 0001).
It thus appears that, under the con-
ditions of the experiment, the resistance
normally evoked by pretreatment with
493494 M. F. A. WOODRUFF, A. GHAFFAR, N. DUNBAR AND V. L. WHITEHEAD
irradiated cells was completely abrogated
by a large i.p. injection of C. parvum
11 days after the cells and partly abro-
gated by a similar injection 5 days before
the cells.
All mice which received 106 irradiated
cells mixed with 0 7 mg C. parvum
developed tumours after challenge with
105 or 107 viable cells, and the mean
relative growth rate was the same after
107 cells, and only marginally less after
105 cells, than in the corresponding un-
treated controls. After challenge with
104 viable cells, however, the incidence
of tumours in the treated mice was
significantly less than in the controls
(comparing groups 9 and 1 of Table II
after challenge with 104 viable cells:
P = 0-001). It thus appears that at
this dosage C. parvum abrogated the
development of resistance to a great
extent but not completely. Smaller
doses had little effect. A dose of 0 35
mg (Table II, group 10) appeared to
cause slight abrogation as judged by the
response to 105 cells, though not by
the response to a larger challenge. With
a dose of 0 09 mg, the immunizing effect
of the irradiated cells was, if anything,
actually increased (compare groups 2
and 11 of Table II). Neither the dif-
ference in tumour incidence nor the
difference in tumour growth rate in mice
which developed tumour are themselves
significant, but if the group mean tumour
diameter on Day 15 of all animals in the
group are compared by a t test (scoring
animals without tumours as having tu-
mours of diameter 0) the difference
based on a single-tailed test is just
significant at the P = 0.05 level (t = 1*96
for 10 degrees of freedom).
DISCUSSION
It is apparent that, with the tumour
used in these experiments, the resistance
to live challenge which develops after
injection of an optimal dose of irradiated
tumour cells is not absolute but can
be over-ridden ifthe challenging inoculum
is sufficiently large. It is also clear
that the immunogenicity of irradiated
tumour cells is lost if the dose of irradia-
tion is too large. It seems likely that
these conclusions would hold good also
for other immunogenic tumours.
The observations on the abrogation
of the resistance resulting from injection
of irradiated tumour cells by injection
of C. parvum confirm and extend those
of Smith and Scott (1972), and highlight
the need for caution in clinical trials
of combined procedures of this kind.
The degree of abrogation depends inter
alia on the dose of C. parvum, the time
at which it is given in relation to the
irradiated cells, and the route ofinjection.
When C. parvum is mixed with irradiated
cells large doses are more prone to
cause abrogation than small doses, and
there is a suggestion that with a very
small dose (inthese experiments 0 09 mg),
instead of abrogation, immunization may
actually be enhanced. When the dose
is still further reduced there is no effect
in either direction.
Our attempts to elucidate the mech-
anism underlying this phenomenon are
as yet inconclusive. As we have already
briefly reported (Woodruff, Ghaffar and
Dunbar, 1975), spleen cells from mice
pretreated with C. parvum and irradiated
tumour cells may be cytotoxic for the
tumour in vitro even though the mice
show no increased resistance to challenge
with viable tumour cells. In the light
of this finding we suggested that the
abrogation of resistance in vivo might
be caused by a blocking factor in the
serum, and preliminary experiments ap-
peared to lend some support to this
conjecture. We do not know, however,
to what extent, if any, the cell-mediated
cytotoxicity in vitro is specific for the
tumour, and further investigation has
failed to confirm the existence of a
blocking factor. Another possibility,
which is currently being investigated,
is that administration of C. parvum
under the conditions of the experiment
results in the development of suppressorEFFECT OF C. PARVUM ON IMMUNIZATION 495
T-cells. For the time being, however,
the question of mechanism must be
regarded as 8ub judice.
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